Zhejiang Hisun Pharmaceutical Company Overview
- Year Founded
-
1956
- Status
-
Public
- Employees
-
8,751
- Stock Symbol
-
600267
- Investments
-
14
- Share Price
-
$1.82
- (As of Friday Closing)
Zhejiang Hisun Pharmaceutical Company General Information
Description
Zhejiang Hisun Pharmaceutical Co Ltd is a China-based pharmaceutical company. It is focused on the research, development, and distribution of pharmaceuticals. It produces and supplies antibiotics and anticancer drugs. The company's research channels cover indications like anticancer, cardiovascular, anti-infective, anti-parasitic, immunosuppressant and others. Its product portfolio includes active pharmaceutical ingredients like Anastrozole, Docetaxel, Methotrexate, and others and finished dosages such as letrozole tablets, anastrozole tablets, injection mitomycin, and others.
Contact Information
Website
www.hisunpharm.comCorporate Office
- Number 46 Waisha Road
- Jiaojiang District
- Taizhou, Zhejiang 318000
- China
Corporate Office
- Number 46 Waisha Road
- Jiaojiang District
- Taizhou, Zhejiang 318000
- China
Zhejiang Hisun Pharmaceutical Company Stock Performance
As of 20-Nov-2026, Zhejiang Hisun Pharmaceutical Company’s stock price is $1.82. Its current market cap is $2.14B with 1.18B shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.82 | $1.88 | $1.37 - $2.22 | $2.14B | 1.18B | 31.6M | $0.15 |
Zhejiang Hisun Pharmaceutical Company Financials Summary
As of 30-Sep-2026, Zhejiang Hisun Pharmaceutical Company has a trailing 12-month revenue of $1.33B.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 2,202,487 | 1,999,718 | 1,834,807 | 2,326,380 |
| Revenue | 1,327,149 | 1,466,996 | 1,441,057 | 1,420,883 |
| EBITDA | 238,907 | 260,485 | 270,003 | 163,553 |
| Net Income | 177,794 | 75,189 | 83,783 | (13,169) |
| Total Assets | 2,061,602 | 2,151,239 | 2,187,981 | 2,484,733 |
| Total Debt | 230,695 | 439,002 | 581,314 | 802,984 |
Zhejiang Hisun Pharmaceutical Company Comparisons
Industry
Financing
Details
Zhejiang Hisun Pharmaceutical Company Competitors (27)
One of Zhejiang Hisun Pharmaceutical Company’s 27 competitors is Roche, a Corporation company based in Basel, Switzerland.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Roche | Corporation | Basel, Switzerland | ||||
| GSK | Corporation | London, United Kingdom | ||||
| Teva Pharmaceutical Industries | Corporation | Tel Aviv, Israel | ||||
| Biocon | Formerly PE-Backed | Bengaluru, India | ||||
| Wockhardt | Corporation | Mumbai, India |
Zhejiang Hisun Pharmaceutical Company Patents
Zhejiang Hisun Pharmaceutical Company Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026223649-A1 | Azabicyclic derivative, preparation method therefor and use thereof | Pending | 21-Apr-2025 | ||
| WO-2026214668-A1 | Azaheterocyclic aminocarboxylate derivative, preparation method therefor, and use thereof | Pending | 11-Apr-2025 | ||
| WO-2026208980-A1 | Salt of aromatic amide derivative and preparation method therefor and use thereof | Pending | 03-Apr-2025 | ||
| WO-2026179869-A1 | Substituted aromatic derivative, and preparation method therefor and use thereof | Pending | 26-Feb-2025 | ||
| WO-2026179879-A1 | Tetrahydropyridazine derivative, and preparation method therefor and use thereof | Pending | 26-Feb-2025 |
Zhejiang Hisun Pharmaceutical Company Signals
Zhejiang Hisun Pharmaceutical Company Investments & Acquisitions (14)
Zhejiang Hisun Pharmaceutical Company’s most recent deal was a PE Growth/Expansion with Sundoc for . The deal was made on 30-Jun-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Sundoc | 30-Jun-2026 | PE Growth/Expansion | Drug Discovery | ||
| JSIAMA Biopharmaceuticals | 26-Mar-2025 | Early Stage VC | Biotechnology | ||
| Fanxi | 25-Apr-2024 | Later Stage VC | Drug Discovery | ||
| Angel Pharmaceuticals | 06-Oct-2020 | Early Stage VC | Drug Discovery | ||
| Hanhui Pharmaceutical | 08-Jul-2020 | Secondary Transaction - Private | Pharmaceuticals |
Zhejiang Hisun Pharmaceutical Company ESG
Risk Overview
Risk Rating
Updated March, 31, 2025
40.5 | Severe Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,271
Rank
Percentile
Pharmaceuticals
Industry
of 908
Rank
Percentile
Pharmaceuticals
Subindustry
of 406
Rank
Percentile
Zhejiang Hisun Pharmaceutical Company Exits (6)
Zhejiang Hisun Pharmaceutical Company’s most recent exit was on 19-Dec-2017 from DTRM Biopharma. The exit was categorized as with 5 buyers.
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| DTRM Biopharma | 19-Dec-2017 | Completed |
|
||
| Photolitec | 07-Jan-2016 | Completed |
|
||
| IMD Natural Solutions | 31-Aug-2015 | Completed |
|
||
| Pharmaceutical Industry | 08-Oct-2013 | Completed |
|
||
| Sagent Pharmaceuticals | 01-Aug-2010 | Early Stage VC | Completed |
|
Zhejiang Hisun Pharmaceutical Company Affiliates
Subsidiaries (3)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Hisun SuliKang | Taizhou, China | 2015 | |
| Hanhui Pharmaceutical | Hangzhou, China | 2012 | |
| Hisun (China) | Hangzhou, China | 2009 |
Zhejiang Hisun Pharmaceutical Company FAQs
-
When was Zhejiang Hisun Pharmaceutical Company founded?
Zhejiang Hisun Pharmaceutical Company was founded in 1956.
-
Where is Zhejiang Hisun Pharmaceutical Company headquartered?
Zhejiang Hisun Pharmaceutical Company is headquartered in Taizhou, China.
-
What is the size of Zhejiang Hisun Pharmaceutical Company?
Zhejiang Hisun Pharmaceutical Company has 8,751 total employees.
-
What industry is Zhejiang Hisun Pharmaceutical Company in?
Zhejiang Hisun Pharmaceutical Company’s primary industry is Biotechnology.
-
Is Zhejiang Hisun Pharmaceutical Company a private or public company?
Zhejiang Hisun Pharmaceutical Company is a Public company.
-
What is Zhejiang Hisun Pharmaceutical Company’s stock symbol?
The ticker symbol for Zhejiang Hisun Pharmaceutical Company is 600267.
-
What is the current stock price of Zhejiang Hisun Pharmaceutical Company?
As of 20-Nov-2026 the stock price of Zhejiang Hisun Pharmaceutical Company is $1.82.
-
What is the current market cap of Zhejiang Hisun Pharmaceutical Company?
The current market capitalization of Zhejiang Hisun Pharmaceutical Company is $2.14B.
-
What is Zhejiang Hisun Pharmaceutical Company’s current revenue?
The trailing twelve month revenue for Zhejiang Hisun Pharmaceutical Company is $1.33B.
-
Who are Zhejiang Hisun Pharmaceutical Company’s competitors?
Roche, GSK, Teva Pharmaceutical Industries, Biocon, and Wockhardt are some of the 27 competitors of Zhejiang Hisun Pharmaceutical Company.
-
What is Zhejiang Hisun Pharmaceutical Company’s annual earnings per share (EPS)?
Zhejiang Hisun Pharmaceutical Company’s EPS for 12 months was $0.15.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process